Inflammation synergizes with a cell’s intrinsic genetic program to promote the development of pancreatic cancer.

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

Metastatic pancreatic cancer — cancer that has spread from the pancreas to other tissues and is responsible for most patient deaths — changes its metabolism and is “reprogrammed” for optimal malignancy, according to new findings reported Jan. 16 in Nature Genetics. It may be possible to reverse the malignant reprogramming to treat metastatic pancreatic cancer, […]